Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes.
作者信息
Mathur Vasundhara, Wasden Katherine, Shin Thomas H, Medhati Pourya, Nimeri Abdelrahman A, Tavakkoli Ali, Sheu Eric G
机构信息
Laboratory for Surgical and Metabolic Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
JAMA Surg. 2025 May 1;160(5):594-596. doi: 10.1001/jamasurg.2025.0001.
Abstract
摘要
相似文献
1
Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes.新辅助司美格鲁肽、减重手术与总体结局
JAMA Surg. 2025 May 1;160(5):594-596. doi: 10.1001/jamasurg.2025.0001.
2
Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.胰高血糖素样肽-1受体激动剂利拉鲁肽和司美格鲁肽12个月治疗对减肥手术后体重反弹的疗效：一项真实世界回顾性观察研究
BMC Endocr Disord. 2025 Apr 7;25(1):93. doi: 10.1186/s12902-025-01913-4.
3
Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease.胰高血糖素样肽 1/葡萄糖依赖性胰岛素促分泌多肽受体激动剂（替尔泊肽）与减重手术治疗对体重减轻和非酒精性脂肪性肝病的影响。
Med Princ Pract. 2024;33(5):478-490. doi: 10.1159/000540534. Epub 2024 Jul 24.
4
What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue.什么对减肥最有效？减肥手术与胰高血糖素样肽-1类似物的安全性和有效性比较综述。
Cureus. 2023 Sep 29;15(9):e46197. doi: 10.7759/cureus.46197. eCollection 2023 Sep.
5
The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis.利拉鲁肽每周 1 次治疗减重或减重不足的非 2 型糖尿病患者的疗效：一项回顾性分析。
Obes Surg. 2022 Oct;32(10):3280-3288. doi: 10.1007/s11695-022-06211-9. Epub 2022 Jul 25.
6
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.《减重手术后患者应用胰高血糖素样肽-1 受体激动剂：系统评价和荟萃分析》
Obes Surg. 2024 May;34(5):1653-1664. doi: 10.1007/s11695-024-07175-8. Epub 2024 Mar 19.
7
Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.胰高血糖素样肽-1受体激动剂在代谢性减重手术后体重复发或临床反应欠佳管理中的疗效与安全性：一项荟萃分析
Obes Surg. 2025 May;35(5):1947-1960. doi: 10.1007/s11695-025-07856-y. Epub 2025 Apr 16.
8
Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study.减肥与代谢手术前胰高血糖素样肽-1受体激动剂的使用模式：一项多中心研究。
Surg Obes Relat Dis. 2025 Feb;21(2):121-126. doi: 10.1016/j.soard.2024.09.010. Epub 2024 Oct 9.
9
Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery.司美格鲁肽与身体塑形手术后非糖尿病患者的术后结局
Aesthet Surg J. 2025 Mar 17;45(4):381-386. doi: 10.1093/asj/sjae241.
10
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.利拉鲁肽和司美格鲁肽作为减重手术后体重反弹的治疗药物的疗效：一项回顾性观察研究。
Obes Surg. 2023 Apr;33(4):1017-1025. doi: 10.1007/s11695-023-06484-8. Epub 2023 Feb 11.
引用本文的文献
1
Exploratory Assessment of Preoperative GLP-1 Receptor Agonists Before Sleeve Gastrectomy: A Retrospective Matched Analysis.袖状胃切除术前GLP-1受体激动剂的探索性评估：一项回顾性匹配分析
Obes Surg. 2025 Sep 10. doi: 10.1007/s11695-025-08258-w.
2
Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US.美国接受减肥手术的个体中胰高血糖素样肽-1激动剂的使用情况。
JAMA Surg. 2025 Aug 27. doi: 10.1001/jamasurg.2025.3089.
3
Preoperative Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery Outcomes: A Systematic Review.术前胰高血糖素样肽-1受体激动剂与减肥手术效果：一项系统评价
Obes Surg. 2025 Aug 9. doi: 10.1007/s11695-025-08137-4.
4
Effects of preoperative glucagon-like peptide-1 receptor agonist therapy on weight loss following bariatric surgery.术前胰高血糖素样肽-1受体激动剂治疗对减肥手术后体重减轻的影响。
Surg Endosc. 2025 Jun 9. doi: 10.1007/s00464-025-11838-7.
5
Pediatric Metabolic and Bariatric Surgery and Antiobesity Medications: Weighing Efficacy, Risks, and Future Directions.小儿代谢与减重手术及抗肥胖药物：权衡疗效、风险与未来方向
J Pediatr. 2025 Aug;283:114610. doi: 10.1016/j.jpeds.2025.114610. Epub 2025 Apr 17.
本文引用的文献
1
Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery.司美格鲁肽 2.4mg/周用于严重肥胖患者的体重减轻，无论是否有减重手术史。
Obesity (Silver Spring). 2024 Jan;32(1):50-58. doi: 10.1002/oby.23922. Epub 2023 Nov 5.
2
Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.在等待减肥手术期间使用GLP-1受体激动剂（3.0毫克利拉鲁肽和1.0毫克司美格鲁肽）治疗的影响。
Biomedicines. 2023 Oct 13;11(10):2785. doi: 10.3390/biomedicines11102785.
3
Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study.减肥手术前高危患者使用胰高血糖素样肽-1激动剂：一项队列研究。
Surg Endosc. 2023 Dec;37(12):9509-9513. doi: 10.1007/s00464-023-10387-1. Epub 2023 Sep 12.
4
Preoperative and early adjuvant weight loss medications in bariatric surgery patients with body mass index over 60 or suboptimal initial response to surgery.肥胖症手术患者体重指数超过 60 或手术初始反应不佳时的术前和早期辅助减肥药物。
Surg Obes Relat Dis. 2023 Aug;19(8):832-840. doi: 10.1016/j.soard.2023.01.021. Epub 2023 Feb 15.
5
Clinical outcomes of single-stage versus two-stage laparoscopic Roux-en-y gastric bypass in the management of obesity (BMI ≥ 50 kg/m): a retrospective cohort study.单阶段与两阶段腹腔镜 Roux-en-y 胃旁路术治疗肥胖症（BMI≥50kg/m²）的临床结局：一项回顾性队列研究。
Langenbecks Arch Surg. 2022 Dec;407(8):3349-3356. doi: 10.1007/s00423-022-02664-9. Epub 2022 Sep 2.
6
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
Zotero 插件